Navigation Links
FDA Approves 1st in New Class of Type 2 Diabetes Drugs
Date:3/29/2013

FRIDAY, March 29 (HealthDay News) -- The first in a new class of type 2 diabetes drugs was approved Friday by the U.S. Food and Drug Administration.

Invokana (canaglifozin) tablets are to be taken, in tandem with a healthy diet and exercise, to improve blood sugar control in adults with type 2 diabetes.

Invokana belongs to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by blocking the reabsorption of glucose (sugar) by the kidney and increasing glucose excretions in urine, the FDA said in a news release.

"We continue to advance innovation with the approval of new drug classes that provide additional treatment options for chronic conditions that impact public health," Dr. Mary Parks, director of the division of metabolism and endocrinology products in the FDA's Center for Drug Evaluation and Research, said in the news release.

About 24 million Americans have type 2 diabetes, and it accounts for more than 90 percent of diabetes cases diagnosed in the United States, the FDA said. If blood sugar levels are not carefully controlled, there is an increased risk for serious complications, including heart disease, blindness, and nerve and kidney damage, the agency added.

The FDA approval is based on the findings of nine clinical trials involving more than 10,000 patients. Patients who took the drug showed improvement in hemoglobin A1c levels (a measure of blood sugar control) and fasting blood sugar levels.

Invokana should not be used by people with type 1 diabetes or people with type 2 diabetes who have increased ketones in their blood or urine (diabetic ketoacidosis), severe kidney disease, kidney failure or who are on dialysis, the FDA said.

The agency told drug maker Janssen Pharmaceuticals that it must conduct five post-approval studies of the drug to determine the risk of problems such as heart disease, cancer, pancreatitis, liver abnormalities and pregnancy
'/>"/>

Copyright©2012 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. FDA Approves Generic Versions of Plavix
2. FDA Approves Combo Shot for Meningitis, Hib in Kids
3. FDA Approves SonixGPS Needle Guidance Technology for Vascular Access Procedures
4. FDA Approves First New Weight-Loss Drug in More Than a Decade
5. FDA Approves 1st Pill to Help Prevent HIV Infection
6. FDA Approves 2nd New Weight-Loss Drug
7. FDA Approves Flu Vaccine for Coming Season
8. FDA Approves New Once-a-Day HIV Pill
9. FDA Approves New Type of Flu Vaccine
10. Environmental Protection Agency Approves MOMS by OdorXit as a Disinfectant
11. FDA Approves 1st Skin Patch to Combat Migraines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves 1st in New Class of Type 2 Diabetes Drugs
(Date:9/3/2015)... ... 03, 2015 , ... Doctor Kayode Sotonwa can be counted on ... perspective on internal medicine keeps patients happy and healthy, something that is important to ... the season, but even more so in the fall, when holiday eating and seasonal ...
(Date:9/2/2015)... ... September 03, 2015 , ... Leah ... among the most influential leaders in healthcare, will offer the keynote address at ... place October 15-16, 2015, in Palm Harbor, Florida, at the Innisbrook Resort and ...
(Date:9/2/2015)... ... 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA breaks ... nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs (a ... RNA (sgRNA or crRNA) to create a break in the target DNA that causes ...
(Date:9/2/2015)... ... ... to an article published August 12 by International Business Times, a new bill ... grand juries in cases meant to decide if a police officer used deadly or excessive ... in Ferguson and New York City that absolved police officers of charges in the deaths ...
(Date:9/2/2015)... Lauderdale, FL (PRWEB) , ... September 02, 2015 ... ... for Amgen’s Blincyto® (blinatumomab) – in the news recently following a decision by ... hospitalized Medicare patients – is likely to average approximately $71,000 or roughly 40% ...
Breaking Medicine News(10 mins):Health News:Doctor Kayode Sotonwa Highlights Expert Tips for Staying in Shape This Fall 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 2Health News:ACO Coalition Meeting to Feature Leapfrog’s Leah Binder 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4
... study to identify the composition of bacterial populations on the ... Skin, which// is the largest organ in our body harbors ... previously. Researchers said that it appears that the skin, is ... quite novel. ,Researchers found evidence for 182 species ...
... during pregnancy could lead to diabetes and cardio vascular ... women. Among them, those who had a high BP ... atherosclerosis than their counterparts who had a normal BP. ... latest issue of ‘Hypertension’ suggests that calcification of the ...
... latest Government data, there is an alarming rise in suicides ... linked to the plummeting sale of// antidepressants. ,This ... also indicated that youth in their late teens resorted to ... Administration had issued a black box warning on the antidepressants ...
... conducted by Robert Wilson of Rush University Medical Centre of Chicago ... Alzheimer’s like// Dementia. People who are single or socially secluded are ... their life. ,According to this study, a group of ... age group of 80 for a period of four years. A ...
... Worldwide describes a lawsuit from CSPI -Center for Science in ... claims of their new drink. ,According to the ... more calories and hence, an aid to calorie ... soft drink is laced with EGCG or epigallocatechin gallate which ...
... pain in the jaw may be a sign of a heart ... Uruguay.// ,The symptoms are however often overlooked, and especially ... tooth or jaw ache without chest pains, the study said. ... were asked to indicate on a body chart where they experienced ...
Cached Medicine News:Health News:Human Skin Harbors Many More Types of Bacteria 2Health News:Human Skin Harbors Many More Types of Bacteria 3Health News:Human Skin Harbors Many More Types of Bacteria 4Health News:Human Skin Harbors Many More Types of Bacteria 5Health News:Support Claims With Science Not Magic, Beverage Owners Warned 2
(Date:9/2/2015)... , Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , Chief Financial Officer of Neurocrine Biosciences, will be ... New York City . The ... 11:25am ET (8:25am PT).  The presentation will be webcast ... http://www.neurocrine.com .   Listeners are encouraged ...
(Date:9/2/2015)... -- Research and Markets ( ... PharmaBiotech,s new report "Therapeutic Drug Monitoring - ... This report deals with therapeutic drug ... patient care by monitoring drug levels in the ... for improving outcome. TDM is viewed as a ...
(Date:9/2/2015)... MARIETTA, Ga. , Sept. 2, 2015  MiMedx ... regenerative medicine company utilizing human amniotic tissue and ... and therapies for the Wound Care, Surgical, Orthopedic, ... healthcare, today corrected the inaccurate statements published by ... release of September 1, 2015. MTF,s ...
Breaking Medicine Technology:Global Therapeutic Drug Monitoring Technologies, Markets, and Companies Report 2015 - Updated 2015 Analysis with Forecasts to 2024 2MiMedx Corrects A Second Inaccurate MTF Press Release 2MiMedx Corrects A Second Inaccurate MTF Press Release 3
... Inc., a privately,held biopharmaceutical company that specializes ... ophthalmic,pharmaceuticals, today reported the interim month three ... pharmacokinetic (PK) study of Medidur(TM) FA,which Alimera ... Iluvien(TM),if approved by the U.S. Food and ...
... developing proposals to fund clinical studies for early detection ... ... 25 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( http://www.biomoda.com ), a ... the Small,Business Innovation Research (SBIR) and Small Business Technology Transfer,(SBTT) seed ...
Cached Medicine Technology:Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 2Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study 3Small Business Innovation Research Program Awards Grant to Biomoda 2
Detection of Malarial antigen in Human whole blood....
Malaria ( P. Falciparum ) Whole Blood Strip / Cassette...
This is an antigen-capture assay intended for the detection of histidine-rich protein ll (PfHRP-ll), which is released from Malaria-infected red blood cells....
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria)....
Medicine Products: